

Alexander N Orekhov

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3984600/publications.pdf](https://exaly.com/author-pdf/3984600/publications.pdf)

Version: 2025-02-01

269
papers

11,547
citations

23395

54
h-index

30160

96
g-index

280
all docs

280
docs citations

280
times ranked

17657
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Aspects of Inflammation and Lipid Metabolism in Health and Disease: The Role of the Mitochondria. <i>International Journal of Molecular Sciences</i> , 2024, 25, 6299.	4.5	5
2	Role of Cathelicidins in Atherosclerosis and Associated Cardiovascular Diseases. <i>Journal of Molecular Pathology</i> , 2024, 5, 319-334.	1.1	0
3	Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential. <i>Diseases (Basel, Switzerland)</i> , 2024, 12, 226.	2.8	2
4	Rheumatoid Arthritis: What Inflammation Do We Face?. <i>Journal of Molecular Pathology</i> , 2024, 5, 454-465.	1.1	1
5	Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis. <i>Biomedicines</i> , 2023, 11, 503.	3.6	4
6	The Role of Macrophages in the Pathogenesis of Atherosclerosis. <i>Cells</i> , 2023, 12, 522.	4.8	48
7	Creation of Mitochondrial Disease Models Using Mitochondrial DNA Editing. <i>Biomedicines</i> , 2023, 11, 532.	3.6	8
8	The Role of Pericytes in Regulation of Innate and Adaptive Immunity. <i>Biomedicines</i> , 2023, 11, 600.	3.6	12
9	Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of Atherosclerosis Development Have a Substruction?. <i>Cells</i> , 2023, 12, 707.	4.8	6
10	HDL-Based Therapy: Vascular Protection at All Stages. <i>Biomedicines</i> , 2023, 11, 711.	3.6	3
11	Impaired Mitochondrial Function in T-Lymphocytes as a Result of Exposure to HIV and ART. <i>Cells</i> , 2023, 12, 1072.	4.8	4
12	Lipids and Lipoproteins in Atherosclerosis. <i>Biomedicines</i> , 2023, 11, 1424.	3.6	3
13	The Role of Selenium in Atherosclerosis Development, Progression, Prevention and Treatment. <i>Biomedicines</i> , 2023, 11, 2010.	3.6	9
14	Oligosaccharides as Potential Therapeutics against Atherosclerosis. <i>Molecules</i> , 2023, 28, 5452.	4.4	5
15	Atheroprotective Aspects of Heat Shock Proteins. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11750.	4.5	5
16	Potential Application of the Plant-Derived Essential Oils for Atherosclerosis Treatment: Molecular Mechanisms and Therapeutic Potential. <i>Molecules</i> , 2023, 28, 5673.	4.4	3
17	Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. <i>Biomedicines</i> , 2023, 11, 2361.	3.6	0
18	Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential. <i>Biomedicines</i> , 2023, 11, 2411.	3.6	12

#	ARTICLE	IF	CITATIONS
19	Is There a Relationship between Adverse Pregnancy Outcomes and Future Development of Atherosclerosis?. <i>Biomedicines</i> , 2023, 11, 2430.	3.6	2
20	Regulatory T Cells in Atherosclerosis: Is Adoptive Cell Therapy Possible?. <i>Life</i> , 2023, 13, 1931.	2.8	3
21	Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease. <i>Pharmaceuticals</i> , 2023, 16, 1150.	4.4	5
22	Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis. <i>Brazilian Journal of Medical and Biological Research</i> , 2023, 56, .	1.4	1
23	BaZiBuShen alleviates cognitive deficits and regulates Sirt6/NRF2/HO-1 and Sirt6/P53-PGC-1 β -TERT signaling pathways in aging mice. <i>Journal of Ethnopharmacology</i> , 2022, 282, 114653.	5.5	19
24	Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing. <i>International Journal of Molecular Sciences</i> , 2022, 23, 649.	4.5	19
25	The Role of Mitochondrial DNA Mutations in Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 952.	4.5	29
26	The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 254.	3.6	30
27	Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1153.	4.5	19
28	Role of the mtDNA Mutations and Mitophagy in Inflammaging. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1323.	4.5	17
29	Local Accumulation of Lymphocytes in the Intima of Human Aorta Is Associated with Giant Multinucleated Endothelial Cells: Possible Explanation for Mosaicism of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1059.	4.5	5
30	The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 931.	4.5	58
31	Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1332.	4.5	21
32	Vaccination against Atherosclerosis: Is It Real?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2417.	4.5	5
33	Atherosclerosis in HIV Patients: What Do We Know so Far?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2504.	4.5	15
34	Functional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation. <i>Biomedicines</i> , 2022, 10, 452.	3.6	15
35	Mitochondrial Implications in Cardiovascular Aging and Diseases: The Specific Role of Mitochondrial Dynamics and Shifts. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2951.	4.5	7
36	Somatic Mutations of Hematopoietic Cells Are an Additional Mechanism of Body Aging, Conducive to Comorbidity and Increasing Chronification of Inflammation. <i>Biomedicines</i> , 2022, 10, 782.	3.6	2

#	ARTICLE	IF	CITATIONS
37	Editorial: Lipids and Inflammation in Health and Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.6	1
38	The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 460.	4.5	13
39	Lipids and Lipoproteins in Health and Disease. <i>Biomedicines</i> , 2022, 10, 87.	3.6	2
40	Novel Models of Crohn's Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5141.	4.5	2
41	Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5371.	4.5	18
42	Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov. <i>Biomedicines</i> , 2022, 10, 1174.	3.6	10
43	Macrophages in Health and Non-Infectious Disease 2.0. <i>Biomedicines</i> , 2022, 10, 1215.	3.6	1
44	Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6954.	4.5	37
45	Interplay between Zn ²⁺ Homeostasis and Mitochondrial Functions in Cardiovascular Diseases and Heart Ageing. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6890.	4.5	23
46	Aging of Vascular System Is a Complex Process: The Cornerstone Mechanisms. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6926.	4.5	6
47	Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis. <i>Metabolites</i> , 2022, 12, 634.	3.5	4
48	The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7863.	4.5	18
49	Phenotype Diversity of Macrophages in Osteoarthritis: Implications for Development of Macrophage Modulating Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8381.	4.5	23
50	The Role of Mitochondrial Mutations in Chronification of Inflammation: Hypothesis and Overview of Own Data. <i>Life</i> , 2022, 12, 1153.	2.8	9
51	Atheroprotective Effects of <i>Glycyrrhiza glabra</i> L. <i>Molecules</i> , 2022, 27, 4697.	4.4	13
52	Atherosclerosis Specific Features in Chronic Kidney Disease (CKD). <i>Biomedicines</i> , 2022, 10, 2094.	3.6	18
53	From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9738.	4.5	13
54	Effect of Glucose Levels on Cardiovascular Risk. <i>Cells</i> , 2022, 11, 3034.	4.8	17

#	ARTICLE	IF	CITATIONS
55	Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12725.	4.5	13
56	Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis. <i>Biomedicines</i> , 2022, 10, 2639.	3.6	4
57	Molecular Mechanisms Underlying Pathological and Therapeutic Roles of Pericytes in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11663.	4.5	12
58	Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson's Disease. <i>Pharmaceutics</i> , 2022, 14, 2514.	5.2	4
59	Involvement of Bacterial Extracellular Membrane Nanovesicles in Infectious Diseases and Their Application in Medicine. <i>Pharmaceutics</i> , 2022, 14, 2597.	5.2	3
60	Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a Special Focus on Mitochondrial Dysfunction and Genetic Associations. <i>Biomolecular Concepts</i> , 2021, 12, 55-67.	2.7	8
61	Involvement of Oxidative Stress and the Innate Immune System in SARS-CoV-2 Infection. <i>Diseases (Basel)</i> , 2021, 11, 36.	2.8	14
62	Do Mitochondrial DNA Mutations Play a Key Role in the Chronification of Sterile Inflammation? Special Focus on Atherosclerosis. <i>Current Pharmaceutical Design</i> , 2021, 27, 276-292.	2.3	6
63	Role of Telomeres Shortening in Atherogenesis: An Overview. <i>Cells</i> , 2021, 10, 395.	4.8	18
64	Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages. <i>Journal of the American Heart Association</i> , 2021, 10, .	4.3	37
65	Two Subpopulations of Human Monocytes That Differ by Mitochondrial Membrane Potential. <i>Biomedicines</i> , 2021, 9, 153.	3.6	1
66	Autophagy and Mitophagy as Essential Components of Atherosclerosis. <i>Cells</i> , 2021, 10, 443.	4.8	28
67	Mutations of mtDNA in some Vascular and Metabolic Diseases. <i>Current Pharmaceutical Design</i> , 2021, 27, 177-184.	2.3	6
68	Disturbance of Mitochondrial Dynamics and Mitochondrial Therapies in Atherosclerosis. <i>Life</i> , 2021, 11, 165.	2.8	19
69	Pro-inflammatory molecules induce cholesterol accumulation in macrophages: Role of inflammatory response in foam cell formation. <i>Atherosclerosis</i> , 2021, 320, 129-130.	1.2	1
70	Immunopathology of Atherosclerosis and Related Diseases: Focus on Molecular Biology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4080.	4.5	27
71	Macrophages in Health and Non-Infectious Disease. <i>Biomedicines</i> , 2021, 9, 460.	3.6	4
72	Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3923.	4.5	89

#	ARTICLE	IF	CITATIONS
73	Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4459.	4.5	33
74	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2021, 27, 3729-3740.	2.3	10
75	ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4691.	4.5	13
76	Atherosclerosis as Mitochondriopathy: Repositioning the Disease to Help Finding New Therapies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, .	2.6	18
77	The Role of Mitochondrial Dysfunction in Vascular Disease, Tumorigenesis, and Diabetes. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, .	3.6	47
78	Prospects for the Use of Sialidase Inhibitors in Anti-atherosclerotic Therapy. <i>Current Medicinal Chemistry</i> , 2021, 28, 2438-2450.	2.5	5
79	BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF- κ B pathways in aging mice induced by D-galactose and NaNO ₂ . <i>Journal of Ethnopharmacology</i> , 2021, 271, 113810.	5.5	49
80	Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside. <i>Biomedicines</i> , 2021, 9, 600.	3.6	33
81	Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6702.	4.5	68
82	Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7061.	4.5	52
83	The Role of Mitochondrial Mutations and Chronic Inflammation in Diabetes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6733.	4.5	31
84	Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6949.	4.5	17
85	Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development. <i>Biomedicines</i> , 2021, 9, 915.	3.6	49
86	Immunity in Atherosclerosis: Focusing on T and B Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8379.	4.5	28
87	The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8770.	4.5	24
88	Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8990.	4.5	46
89	Macrophages and Foam Cells: Brief Overview of Their Role, Linkage, and Targeting Potential in Atherosclerosis. <i>Biomedicines</i> , 2021, 9, 1221.	3.6	46
90	Fructus Ligustri Lucidi aqueous extract promotes calcium balance and short-chain fatty acids production in ovariectomized rats. <i>Journal of Ethnopharmacology</i> , 2021, 279, 114348.	5.5	17

#	ARTICLE	IF	CITATIONS
91	A comprehensive review on the phytochemistry, pharmacokinetics, and antidiabetic effect of Ginseng. <i>Phytomedicine</i> , 2021, 92, 153717.	7.4	41
92	Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 699.	4.5	15
93	Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. <i>Frontiers in Pharmacology</i> , 2021, 11, .	4.0	185
94	Modification of Tumor Necrosis Factor- α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome. <i>Biology</i> , 2020, 9, 3.	3.0	6
95	A Novel Insight at Atherogenesis: The Role of Microbiome. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, .	3.7	20
96	NLPR3 Inflammasomes and Their Significance for Atherosclerosis. <i>Biomedicines</i> , 2020, 8, 205.	3.6	31
97	NADPH Oxidases and Their Role in Atherosclerosis. <i>Biomedicines</i> , 2020, 8, 206.	3.6	59
98	Endoplasmic Reticulum Stress in Macrophages: The Vicious Circle of Lipid Accumulation and Pro-Inflammatory Response. <i>Biomedicines</i> , 2020, 8, 210.	3.6	29
99	Therapeutic Potential of Heme Oxygenase-1 in Aneurysmal Diseases. <i>Antioxidants</i> , 2020, 9, 1150.	5.8	7
100	Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study. <i>Biology</i> , 2020, 9, 184.	3.0	4
101	Genetics of Arterial-Wall-Specific Mechanisms in Atherosclerosis: Focus on Mitochondrial Mutations. <i>Current Atherosclerosis Reports</i> , 2020, 22, .	4.9	11
102	Lipid Metabolism in Macrophages: Focus on Atherosclerosis. <i>Biomedicines</i> , 2020, 8, 262.	3.6	74
103	Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5472.	4.5	21
104	Sex-Specific Features of Calcific Aortic Valve Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5620.	4.5	50
105	Noninvasive Testing for Diagnosis of Stable Coronary Artery Disease in the Elderly. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6263.	4.5	4
106	Relationship Between Plasma Osteopontin and Arginine Pathway Metabolites in Patients With Overt Coronary Artery Disease. <i>Frontiers in Physiology</i> , 2020, 11, .	3.0	6
107	Impact of Mitochondrial DNA Mutations on Carotid Intima-Media Thickness in the Novosibirsk Region. <i>Life</i> , 2020, 10, 160.	2.8	6
108	Exposure to Zinc Oxide Nanoparticles Disrupts Endothelial Tight and Adherens Junctions and Induces Pulmonary Inflammatory Cell Infiltration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3437.	4.5	17

#	ARTICLE	IF	CITATIONS
109	Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations. <i>Frontiers in Pharmacology</i> , 2020, 11, .	4.0	28
110	Mitochondrial Dysfunction and DNA Damage in the Context of Pathogenesis of Atherosclerosis. <i>Biomedicines</i> , 2020, 8, 166.	3.6	42
111	The Diabetes Mellitusâ€Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1835.	4.5	630
112	In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2097.	4.5	19
113	Carotid Atherosclerosis Progression in Postmenopausal Women Receiving a Mixed Phytoestrogen Regimen: Plausible Parallels with Kronos Early Estrogen Replacement Study. <i>Biology</i> , 2020, 9, 48.	3.0	2
114	Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis. <i>Cells</i> , 2020, 9, 584.	4.8	72
115	The Role of Mitochondria in Cardiovascular Diseases. <i>Biology</i> , 2020, 9, 137.	3.0	58
116	Data on association of mitochondrial heteroplasmy with carotid intima-media thickness in subjects from Russian and Kazakh populations. <i>Data in Brief</i> , 2020, 29, 105136.	1.4	8
117	The Link between Chronic Stress and Accelerated Aging. <i>Biomedicines</i> , 2020, 8, 198.	3.6	76
118	Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 817.	4.5	23
119	Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2992.	4.5	71
120	Lipidâ€based gene delivery to macrophage mitochondria for atherosclerosis therapy. <i>Pharmacology Research and Perspectives</i> , 2020, 8, .	2.3	15
121	Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Responseâ€What is First?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2716.	4.5	23
122	Clinical Effectiveness of a Combination of Black Elder Berries, Violet Herb, and Calendula Flowers in Chronic Obstructive Pulmonary Disease: The Results of a Double-Blinded Placebo-Controlled Study. <i>Biology</i> , 2020, 9, 83.	3.0	0
123	Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment. <i>Biology</i> , 2020, 9, 60.	3.0	90
124	Contribution of Neurotrophins to the Immune System Regulation and Possible Connection to Alcohol Addiction. <i>Biology</i> , 2020, 9, 63.	3.0	13
125	Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 978.	2.6	27
126	Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation. <i>Current Neuropharmacology</i> , 2020, 18, 1064-1075.	4.2	50

#	ARTICLE	IF	CITATIONS
127	Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review) Tj ETQq1 1 0.784314 14 0gBT /Over	1.3	18
128	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. Current Medicinal Chemistry, 2019, 26, 1512-1524.	2.5	18
129	Changes in Mitochondrial Genome Associated with Predisposition to Atherosclerosis and Related Disease. Biomolecules, 2019, 9, 377.	4.4	25
130	The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 3561.	4.5	104
131	MicroRNAs as Potential Biomarkers in Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 5547.	4.5	89
132	Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells. Journal of Clinical Medicine, 2019, 8, 1798.	2.6	51
133	Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima. Biomolecules, 2019, 9, 455.	4.4	15
134	Creation of Cybrid Cultures Containing mtDNA Mutations m.12315G>>A and m.1555G>>A, Associated with Atherosclerosis. Biomolecules, 2019, 9, 499.	4.4	11
135	Pericytes in Atherosclerosis. Advances in Experimental Medicine and Biology, 2019, , 279-297.	0.0	16
136	Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency. Journal of Clinical Lipidology, 2019, 13, 468-480.e8.	2.0	17
137	Sialidase activity in human pathologies. European Journal of Pharmacology, 2019, 842, 345-350.	4.4	62
138	Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 643-653.	2.3	24
139	Fructus Ligustri Lucidi preserves bone quality through the regulation of gut microbiota diversity, oxidative stress, TMAO and Sirt6 levels in aging mice. Aging, 2019, 11, 9348-9368.	2.5	90
140	Profiling of risk of subclinical atherosclerosis: possible interplay of genetic and environmental factors as the update of conventional approach. Vessel Plus, 2019, 2019, .	0.6	2
141	Creation of Cultures Containing Mutations Linked with Cardiovascular Diseases using Transfection and Genome Editing. Current Pharmaceutical Design, 2019, 25, 693-699.	2.3	9
142	Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology. Current Drug Targets, 2019, 20, 938-941.	2.0	5
143	Human Disease Modelling Techniques: Current Progress. Current Molecular Medicine, 2019, 18, 655-660.	2.1	3
144	Potential of anti-inflammatory agents for treatment of atherosclerosis. Experimental and Molecular Pathology, 2018, 104, 114-124.	2.4	121

#	ARTICLE	IF	CITATIONS
145	New biomarkers for diagnosis and prognosis of localized prostate cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 9-16.	14.2	49
146	The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. <i>Immunobiology</i> , 2018, 223, 101-111.	1.1	216
147	The role of mitochondrial dysfunction in cardiovascular disease: a brief review. <i>Annals of Medicine</i> , 2018, 50, 121-127.	3.9	345
148	Modified LDL Particles Activate Inflammatory Pathways in Monocyte-derived Macrophages: Transcriptome Analysis. <i>Current Pharmaceutical Design</i> , 2018, 24, 3143-3151.	2.3	30
149	Mitochondrial diseases caused by mtDNA mutations: a mini-review. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1933-1942.	2.1	58
150	Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 123, 159-167.	2.0	59
151	Response to: Comment on "Role of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosis". <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, .	4.5	1
152	Modified lipoproteins as biomarkers of atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1422-1444.	6.5	20
153	Mitochondrial Genome Mutations Associated with Myocardial Infarction. <i>Disease Markers</i> , 2018, 2018, 1-6.	1.7	17
154	Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: Comparison of samples from Russian and Mexican populations. <i>Data in Brief</i> , 2018, 18, 16-21.	1.4	8
155	Cybrid Models of Pathological Cell Processes in Different Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, .	4.5	18
156	LDL and foam cell formation as the basis of atherogenesis. <i>Current Opinion in Lipidology</i> , 2018, 29, 279-284.	4.1	37
157	HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages. <i>Experimental and Molecular Pathology</i> , 2018, 105, 202-207.	2.4	11
158	Tumor Necrosis Factor- α and C-C Motif Chemokine Ligand 18 Associate with Atherosclerotic Lipid Accumulation In situ and In vitro. <i>Current Pharmaceutical Design</i> , 2018, 24, 2883-2889.	2.3	17
159	Engineered Nanoparticles: Their Properties and Putative Applications for Therapeutic Approaches Utilizing Stem Cells for the Repair of Atherosclerotic Disease. <i>Current Drug Targets</i> , 2018, 19, 1639-1648.	2.0	6
160	Chemokines and Relevant microRNAs in the Atherogenic Process. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 597-608.	2.6	9
161	The phenomenon of atherosclerosis reversal and regression: Lessons from animal models. <i>Experimental and Molecular Pathology</i> , 2017, 102, 138-145.	2.4	29
162	How do macrophages sense modified low-density lipoproteins?. <i>International Journal of Cardiology</i> , 2017, 230, 232-240.	2.2	31

#	ARTICLE	IF	CITATIONS
163	Macrophages and Their Contribution to the Development of Atherosclerosis. Results and Problems in Cell Differentiation, 2017, , 273-298.	0.0	16
164	Impact of the cardiovascular system-associated adipose tissue on atherosclerotic pathology. Atherosclerosis, 2017, 263, 361-368.	1.2	40
165	The effect of maximal vs submaximal exertion on postprandial lipid levels in individuals with and without coronary heart disease. Journal of Clinical Lipidology, 2017, 11, 369-376.	2.0	1
166	Mechanisms of foam cell formation in atherosclerosis. Journal of Molecular Medicine, 2017, 95, 1153-1165.	3.6	466
167	Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis. Annals of Medicine, 2017, 49, 661-677.	3.9	27
168	The impact of FOXO-1 to cardiac pathology in diabetes mellitus and diabetes-related metabolic abnormalities. International Journal of Cardiology, 2017, 245, 236-244.	2.2	36
169	Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation. International Journal of Cardiology, 2017, 227, 66-82.	2.2	49
170	Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie, 2017, 132, 19-27.	3.0	111
171	Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 188-195.	2.3	31
172	Thrombospondins: A Role in Cardiovascular Disease. International Journal of Molecular Sciences, 2017, 18, 1540.	4.5	41
173	Role of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosis. Oxidative Medicine and Cellular Longevity, 2017, 2017, .	4.5	34
174	Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxidative Medicine and Cellular Longevity, 2017, 2017, .	4.5	290
175	Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives. Current Pharmaceutical Design, 2017, 23, .	2.3	9
176	Use of Primary Macrophages for Searching Novel Immunocorrectors. Current Pharmaceutical Design, 2017, 23, 915-920.	2.3	3
177	Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations. Vessel Plus, 2017, , .	0.6	18
178	New markers of atherosclerosis: a threshold level of heteroplasmy in mtDNA mutations. Vessel Plus, 2017, , .	0.6	8
179	Is insulin pro-atherogenic at the cellular level?. Vessel Plus, 2017, , .	0.6	1
180	Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference?. Vessel Plus, 2017, , .	0.6	22

#	ARTICLE	IF	CITATIONS
181	Introduction of the special issue "Atherosclerosis and Related Diseases", Vessel Plus, 2017, , .	0.6	15
182	Monocyte Activation in Immunopathology: Cellular Test for Development of Diagnostics and Therapy. Journal of Immunology Research, 2016, 2016, 1-9.	2.8	33
183	Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes. Stem Cells International, 2016, 2016, .	2.7	15
184	Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis. BioMed Research International, 2016, 2016, 1-13.	2.7	267
185	PPAR in Cardiovascular Disorders. PPAR Research, 2016, 2016, 1-2.	2.7	6
186	The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis. International Journal of Molecular Sciences, 2016, 17, 193.	4.5	65
187	Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women. International Journal of Molecular Sciences, 2016, 17, 1318.	4.5	42
188	Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	2.0	238
189	The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease. Journal of Molecular and Cellular Cardiology, 2016, 97, 47-55.	2.0	149
190	ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Laboratory Investigation, 2016, 96, 708-718.	3.5	71
191	Macrophage-mediated cholesterol handling in atherosclerosis. Journal of Cellular and Molecular Medicine, 2016, 20, 17-28.	4.1	378
192	Evidence based efficacy of herbal preparations in ageing associated cardiovascular disorders. Phytomedicine, 2016, 23, 1065-1067.	7.4	4
193	Immune-inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells. Immunobiology, 2016, 221, 1014-1033.	1.1	54
194	Dataset of mitochondrial genome variants associated with asymptomatic atherosclerosis. Data in Brief, 2016, 7, 1570-1575.	1.4	12
195	Links between atherosclerotic and periodontal disease. Experimental and Molecular Pathology, 2016, 100, 220-235.	2.4	92
196	Analysis of mitochondrial DNA heteroplasmic mutations A1555G, C3256T, T3336C, G15178A, G12315A, G13513A, G14459A, G14846A and G15059A in CHD patients with the history of myocardial infarction. Experimental and Molecular Pathology, 2016, 100, 87-91.	2.4	22
197	Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential. Phytomedicine, 2016, 23, 1190-1197.	7.4	37
198	Cellular mechanisms of human atherosclerosis: Role of cell-to-cell communications in subendothelial cell functions. Tissue and Cell, 2016, 48, 25-34.	2.4	17

#	ARTICLE	IF	CITATIONS
199	Anti-cytokine therapy for prevention of atherosclerosis. <i>Phytomedicine</i> , 2016, 23, 1198-1210.	7.4	25
200	Anti-atherosclerotic effects of garlic preparation in freeze injury model of atherosclerosis in cholesterol-fed rabbits. <i>Phytomedicine</i> , 2016, 23, 1235-1239.	7.4	26
201	CD68/macrosialin: not just a histochemical marker. <i>Laboratory Investigation</i> , 2016, 97, 4-13.	3.5	464
202	LDL electronegativity index: a potential novel index for predicting cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2015, , 525.	2.4	21
203	Role of gut microbiota in the modulation of atherosclerosis-associated immune response. <i>Frontiers in Microbiology</i> , 2015, 6, .	3.9	77
204	Endothelial Barrier and Its Abnormalities in Cardiovascular Disease. <i>Frontiers in Physiology</i> , 2015, 6, .	3.0	178
205	T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. <i>BioMed Research International</i> , 2015, 2015, 1-9.	2.7	96
206	Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling. <i>BioMed Research International</i> , 2015, 2015, 1-18.	2.7	149
207	Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-11.	4.5	18
208	Mosaicism of Mitochondrial Genetic Variation in Atherosclerotic Lesions of the Human Aorta. <i>BioMed Research International</i> , 2015, 2015, 1-9.	2.7	36
209	Heterogeneity of Tregs and the complexity in the IL-12 cytokine family signaling in driving T-cell immune responses in atherosclerotic vessels. <i>Molecular Immunology</i> , 2015, 65, 133-138.	2.1	7
210	Myeloid dendritic cells: Development, functions, and role in atherosclerotic inflammation. <i>Immunobiology</i> , 2015, 220, 833-844.	1.1	60
211	Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery. <i>Journal of Cardiology</i> , 2015, 66, 271-278.	2.3	50
212	Association of mutations in the mitochondrial genome with the subclinical carotid atherosclerosis in women. <i>Experimental and Molecular Pathology</i> , 2015, 99, 25-32.	2.4	15
213	Vascular stem/progenitor cells: current status of the problem. <i>Cell and Tissue Research</i> , 2015, 362, 1-7.	2.8	28
214	Mutations of mitochondrial genome in carotid atherosclerosis. <i>Frontiers in Genetics</i> , 2015, 6, .	2.4	12
215	Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance. <i>Frontiers in Microbiology</i> , 2015, 5, .	3.9	61
216	Phenomenon of individual difference in human monocyte activation. <i>Experimental and Molecular Pathology</i> , 2015, 99, 151-154.	2.4	12

#	ARTICLE	IF	CITATIONS
217	Study of the activated macrophage transcriptome. <i>Experimental and Molecular Pathology</i> , 2015, 99, 575-580.	2.4	24
218	Changes in transcriptome of macrophages in atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1163-1173.	4.1	84
219	Quantitative analysis of the expression of caspase 3 and caspase 9 in different types of atherosclerotic lesions in the human aorta. <i>Experimental and Molecular Pathology</i> , 2015, 99, 1-6.	2.4	12
220	Innervation of the arterial wall and its modification in atherosclerosis. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2015, 193, 7-11.	3.3	30
221	Association of mitochondrial mutations with the age of patients having atherosclerotic lesions. <i>Experimental and Molecular Pathology</i> , 2015, 99, 717-719.	2.4	10
222	Neutrophil's weapons in atherosclerosis. <i>Experimental and Molecular Pathology</i> , 2015, 99, 663-671.	2.4	44
223	Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases. <i>Current Pharmaceutical Design</i> , 2015, 21, 1158-1163.	2.3	25
224	Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation. <i>Current Pharmaceutical Design</i> , 2015, 21, 1118-1123.	2.3	8
225	Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women. <i>Current Pharmaceutical Design</i> , 2015, 22, 152-163.	2.3	16
226	Mitochondrial genome sequencing in atherosclerosis: what's next?. <i>Current Pharmaceutical Design</i> , 2015, 22, 390-396.	2.3	9
227	Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 338-350.	2.6	48
228	Intimal pericytes as the second line of immune defence in atherosclerosis. <i>World Journal of Cardiology</i> , 2015, 7, 583.	2.2	22
229	Approach to Reduction of Blood Atherogenicity. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-8.	4.5	12
230	Role of Endoplasmic Reticulum Stress in Atherosclerosis and Diabetic Macrovascular Complications. <i>BioMed Research International</i> , 2014, 2014, 1-14.	2.7	60
231	Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 12807-12841.	4.5	74
232	Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. <i>Frontiers in Physiology</i> , 2014, 5, .	3.0	28
233	Low Density Lipoprotein-Containing Circulating Immune Complexes: Role in Atherosclerosis and Diagnostic Value. <i>BioMed Research International</i> , 2014, 2014, 1-7.	2.7	40
234	Quantitative Assessment of Heteroplasmy of Mitochondrial Genome: Perspectives in Diagnostics and Methodological Pitfalls. <i>BioMed Research International</i> , 2014, 2014, 1-9.	2.7	36

#	ARTICLE	IF	CITATIONS
235	Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. <i>Frontiers in Physiology</i> , 2014, 5, .	3.0	61
236	Mitochondrial Aging and Age-Related Dysfunction of Mitochondria. <i>BioMed Research International</i> , 2014, 2014, 1-7.	2.7	333
237	The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells. <i>Cardiovascular Research</i> , 2014, 103, 438-451.	5.6	50
238	Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. <i>Immunology Letters</i> , 2013, 151, 10-22.	2.4	52
239	Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. <i>International Journal of Cardiology</i> , 2013, 166, 747-748.	2.2	9
240	Changes of mitochondria in atherosclerosis: Possible determinant in the pathogenesis of the disease. <i>Atherosclerosis</i> , 2013, 227, 283-288.	1.2	55
241	Lipid Regulators during Atherogenesis: Expression of LXR, PPAR, and SREBP mRNA in the Human Aorta. <i>PLoS ONE</i> , 2013, 8, e63374.	2.5	14
242	Vascular Extracellular Matrix in Atherosclerosis. <i>Cardiology in Review</i> , 2013, 21, 270-288.	1.3	94
243	Changes of lysosomes in the earliest stages of the development of atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 626-635.	4.1	15
244	Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications. <i>Current Pharmaceutical Design</i> , 2013, 19, 5942-5953.	2.3	26
245	Association of Mitochondrial Genetic Variation with Carotid Atherosclerosis. <i>PLoS ONE</i> , 2013, 8, e68070.	2.5	39
246	Anti-Atherosclerotic Therapy Based on Botanicals. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2013, 8, 56-66.	1.7	44
247	Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension. <i>World Journal of Cardiology</i> , 2013, 5, 132.	2.2	8
248	Mitochondrial Mutations are Associated with Atherosclerotic Lesions in the Human Aorta. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-5.	3.8	43
249	Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. <i>Drug Delivery</i> , 2012, 19, 392-405.	7.9	35
250	Widespread distribution of HLA-DR-expressing cells in macroscopically undiseased intima of the human aorta: A possible role in surveillance and maintenance of vascular homeostasis. <i>Immunobiology</i> , 2012, 217, 558-568.	1.1	19
251	Monocytes as a diagnostic marker of cardiovascular diseases. <i>Immunobiology</i> , 2012, 217, 476-482.	1.1	106
252	Mitochondrial dysfunction and mitochondrial DNA mutations in atherosclerotic complications in diabetes. <i>World Journal of Cardiology</i> , 2012, 4, 148.	2.2	18

#	ARTICLE	IF	CITATIONS
253	Pluronic Block Copolymers Inhibit Low Density Lipoprotein Self-Association. <i>Lipids</i> , 2012, 47, 995-1000.	1.5	8
254	Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis. <i>Journal of Clinical Immunology</i> , 2012, 33, 489-495.	3.4	23
255	Mutation C3256T of Mitochondrial Genome in White Blood Cells: Novel Genetic Marker of Atherosclerosis and Coronary Heart Disease. <i>PLoS ONE</i> , 2012, 7, e46573.	2.5	25
256	Musashi-1 expression in atherosclerotic arteries and its relevance to the origin of arterial smooth muscle cells: Histopathological findings and speculations. <i>Atherosclerosis</i> , 2011, 215, 355-365.	1.2	8
257	Correlation between lipid deposition, immune-inflammatory cell content and MHC class II expression in diffuse intimal thickening of the human aorta. <i>Atherosclerosis</i> , 2011, 219, 171-183.	1.2	18
258	The Interaction of Plasma Sialylated and Desialylated Lipoproteins with Collagen from the Intima and Media of Uninvolved and Atherosclerotic Human Aorta. <i>Journal of Lipids</i> , 2011, 2011, 1-8.	1.6	6
259	The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. <i>Lipids in Health and Disease</i> , 2010, 9, 119.	3.8	71
260	Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. <i>Hypertension Research</i> , 2009, 32, 433-437.	3.4	50
261	Lipid-Lowering Effects of Time-Released Garlic Powder Tablets in Double-Blinded Placebo-Controlled Randomized Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 334-338.	2.2	60
262	Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study. <i>Acta Diabetologica</i> , 2007, 45, 1-6.	2.3	85
263	Evaluation of Cell Proliferation in Human Atherosclerotic Lesions. , 2001, , 213-218.		2
264	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 1998, 183, 141-146.	3.2	10
265	Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions. <i>Atherosclerosis</i> , 1998, 139, 41-48.	1.2	60
266	Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. <i>Atherosclerosis</i> , 1997, 135, 19-27.	1.2	102
267	Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. <i>International Journal of Cardiology</i> , 1997, 62, S67-S77.	2.2	16
268	Adult human aortic cells in primary culture: heterogeneity in shape. <i>Heart and Vessels</i> , 1986, 2, 193-201.	1.2	21
269	Mitochondrial mutations associated with cardiac angina. <i>Vessel Plus</i> , 0, 2019, .	0.6	4